Digest Network Come funziona
Network
/
Società
Fa
Non verificato

Faeth Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

14 comunicati stampa

Guarda tutti i comunicati
01/09/2026
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
17/08/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
07/08/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
04/08/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
27/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
20/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
20/10/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
19/10/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
30/09/2025
Software
Scienza
Associazioni/Professionisti
Farmaceutica
Oncologia
Tecnica
Biotecnologia
Salute
Industria
Faeth Therapeutics’ R&D Platform Delivers First Cross-Disease Validation Beyond Oncology
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
24/09/2025
Eventi
Industria
Biotecnologia
Tecnica
Salute
Farmaceutica
Oncologia
Scienza
Software
Fitness
Medicina - Varie
Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0